Ideas
Mega-cap tech faces slowing growth, buybacks
MAG 7 and mega-cap tech leadership is fading: only two MAG 7 stocks outperformed the S&P 500 last year versus five in 2024; tech/MAG 7 earnings growth is forecast to slow from 30-35% to 13%; their buybacks are apt to keep falling as hyperscaler capex rises from about 60% to 80% of operating cash flow; and GenAI IPOs could crowd out mega-cap tech. This makes the concentrated mega-cap tech complex less attractive as the market broadens.
Market broadening favors equal-weight S&P 500
The market is deconcentrating/broadening out from the top 10 companies and MAG 7, with the equal-weighted S&P 500 already outperforming the cap-weighted benchmark for at least two months. She expects this to persist in 2026 because non-MAG 7 S&P 500 earnings growth is forecast to accelerate from about 6% to 19%, while tech/MAG 7 earnings growth slows from 30-35% to 13%; tech buybacks are also falling as capex consumes more operating cash flow, and GenAI IPOs may crowd out mega-cap tech.
Passive S&P 500 gains stay below 10%
She expects the passive S&P 500 index gain to be under 10% in 2026, below consensus year-end targets of 7500-7800, because the top-heavy mega-cap tech complex is losing leadership and the broadening is reducing index concentration benefits. Active stock selection should have more opportunity even as passive index returns are more muted.
Rotate from speculative small caps to quality
She recommends taking profits in high-beta, unprofitable, small-cap, micro-cap, and speculative equities and redeploying into large-cap core and quality names. This is part of rebalancing for strategic diversification and avoiding single-name concentration as market leadership broadens.
Rotate from speculative small caps to quality
She recommends taking profits in high-beta, unprofitable, small-cap, micro-cap, and speculative equities and redeploying into large-cap core and quality names. This is part of rebalancing for strategic diversification and avoiding single-name concentration as market leadership broadens.
Favor GenAI beneficiaries in financials, healthcare, energy
She favors broadening into GenAI productivity beneficiaries, which are likely to be in financials, healthcare, and energy. These sectors are part of the rotation away from concentrated mega-cap tech, with financials and healthcare already starting to shine and non-tech S&P 500 earnings growth expected to accelerate.
Add emerging markets for diversification
She recommends adding to rest of world equities, focusing on emerging markets, as part of broadening diversification away from concentrated US equity leadership and toward additional equity opportunities.
Deploy 2026 vintages in private markets
She suggests preparing for better liquidity opportunities in private markets and planning 2026 vintage deployments in venture capital, growth private equity, and private commercial real estate. This is an allocation toward private-market diversification and away from public single-name concentration.
This Morgan Stanley video, published January 27, 2026,
features Lisa Shalett
discussing MAGS, Mega-Cap Tech, RSP, SPY, QUAL, Speculative small/micro-cap equities, High-beta unprofitable equities, XLF, XLE, XLV, EEM, VXUS, Venture Capital, Growth private equity, Private Commercial Real Estate.
8 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lisa Shalett
· Tickers:
MAGS,
Mega-Cap Tech,
RSP,
SPY,
QUAL,
Speculative small/micro-cap equities,
High-beta unprofitable equities,
XLF,
XLE,
XLV,
EEM,
VXUS,
Venture Capital,
Growth private equity,
Private Commercial Real Estate